In 2006 Santaris Pharma a/s signed an agreement with Enzon Pharmaceuticals worth >$200m in milestone payments, including two LNA drugs at the pre-clinical stage (EZN2968 and EZN3042) and co-development of six cancer target drugs selected by Enzon. In 2008, as a testimony to the strength of Santaris Pharma's Drug Discovery Engine, we completed the delivery of the LNA drugs within the agreed upon specifications against each of the six remaining targets, all within only 24 months of entering the agreement. Moving forward Enzon is committed to the late stage pre-clinical and clinical development of these lead candidates. Santaris Pharma retains the important commercial rights to the drugs within Europe.

In 2007 Santaris Pharma a/s signed an agreement with GlaxoSmithKline potentially worth > $700m in milestone payments. Under the terms of the agreement Santaris Pharma will discover and develop LNA drugs against four viral targets specified by GlaxoSmithKline and will advance them to clinical proof-of-concept. In 2008, the first year of the collaboration, scientists from Santaris Pharma along with their collaborators at GlaxoSmithKline produced a bevy of potential lead compounds directed towards the first infectious disease target covered by the agreement.

In 2008 Santaris Pharma a/s and Wyeth Pharmaceuticals formed an alliance potentially worth $800m in milestone payments to Santaris Pharma. Under the terms of the agreement, Santaris Pharma will deliver LNA drugs against up to 10 messengerRNA and microRNA targets selected by Wyeth. Wyeth will be responsible for all pre-clinical and clinical development and world-wide commercialization.